Tacrolimus does not accentuate hepatic damage due to hypoperfusion

Ron Ben Abraham, Ivgeni Isartal, Richard Nakache, Vallery Rudick, Daniel Ogorek, Gideon Paret, Avi Weinbroum

Research output: Contribution to journalArticlepeer-review


Deterioration of hepatic function following liver transplantation is a known complication, sometimes attributed to the use of cyclosporin A. Reaction to tacrolimus (Prograf), a relatively new and effective immunosuppressant drug, is thought to result in a much lower grade of organ dysfunction, especially in the transplanted liver. Using the ex-vivo rat model of isolated perfused liver, we evaluated hepatocellular damage and oxygen extraction when tacrolimus was administered following liver hypoperfusion. Tacrolimus did not worsen hepatic dysfunction caused by the hypoperfusion. Therefore using tacrolimus in the perioperative period might be safer than cyclosporin A, which tends to worsen hepatic damage in the presence of hypoperfusion.

Original languageEnglish
Pages (from-to)817-819+911
Issue number10
StatePublished - 15 May 2000


Dive into the research topics of 'Tacrolimus does not accentuate hepatic damage due to hypoperfusion'. Together they form a unique fingerprint.

Cite this